Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- SUEVEY
August 8, 2011
- Pregabalin to Be Recommended as 1st-line Drug in New GLs for Peripheral Neuropathic Pain
August 8, 2011
- Takeda Resubmits NDA for DPP-4 Inhibitor in the US
August 8, 2011
- Takara Bio Announces TCR Gene Therapy Collaboration in China
August 8, 2011
- MIC to Test Electronic Prescribing System
August 8, 2011
- Korosho's New GLs Call For Use of IT to Distribute Safety Info.
August 8, 2011
- Takeda to Start Multinational PIII Trial for TAK-875 in FY2011
August 8, 2011
- R&D Spending Fell, Discontinued Clinical Trials Increased in 2010: Thomson Reuters
August 8, 2011
- Kyowa Kirin Files for PD Treatment KW-6500 in Japan
August 8, 2011
- Nippon Chemiphar Discontinues Development of NC-2300
August 8, 2011
- Eve No. 1 OTC Analgesic/Antipyretic Drug 3 Months in a Row
August 8, 2011
- R-Tech Ueno Discontinues PI Study of Hypotrichosis Drug in UK
August 8, 2011
- Marketing Expenses Up 1.5% to US$91 Bil. in 2010: CSD Survey
August 8, 2011
- Taiho's TAS-102 Prolongs OS in mCRC: JSMO Annual Meeting
August 8, 2011
- Oncology Products to Contribute to Astellas' Business from 2018 Onward: President Hatanaka
August 8, 2011
- Avastin's Efficacy in Combination with FOLFIRI for Colon Cancer Confirmed in Domestic PII Study
August 8, 2011
- Shionogi to Enter Chinese Market by Acquiring Local Company
August 8, 2011
- BioWa Licenses Potelligent Technology to arGEN-X
August 8, 2011
- Medipal, JCR Pharm. Announce Tie-up; Medipal to Invest in Drug Development
August 8, 2011
- Toyama Chemical to Construct New Pharmacology Research Lab
August 8, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…